0
0
Read Time:9 Second
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release, titled Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint. |SUBJECT: Press Release
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
